JPMorgan Chase & Co. Raises Stock Position in Fulgent Genetics, Inc. (NASDAQ:FLGT)

JPMorgan Chase & Co. grew its position in Fulgent Genetics, Inc. (NASDAQ:FLGTFree Report) by 113.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 338,044 shares of the company’s stock after buying an additional 179,477 shares during the period. JPMorgan Chase & Co. owned 1.11% of Fulgent Genetics worth $7,346,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in FLGT. Rhumbline Advisers grew its position in Fulgent Genetics by 0.9% in the second quarter. Rhumbline Advisers now owns 68,210 shares of the company’s stock worth $1,338,000 after acquiring an additional 637 shares during the period. Marquette Asset Management LLC lifted its stake in shares of Fulgent Genetics by 13.7% in the 3rd quarter. Marquette Asset Management LLC now owns 9,908 shares of the company’s stock valued at $215,000 after purchasing an additional 1,191 shares during the last quarter. Centiva Capital LP grew its holdings in shares of Fulgent Genetics by 16.5% during the 3rd quarter. Centiva Capital LP now owns 12,538 shares of the company’s stock worth $272,000 after purchasing an additional 1,774 shares during the period. Point72 DIFC Ltd acquired a new stake in shares of Fulgent Genetics during the 3rd quarter worth about $46,000. Finally, Public Sector Pension Investment Board raised its holdings in Fulgent Genetics by 7.1% in the 2nd quarter. Public Sector Pension Investment Board now owns 44,772 shares of the company’s stock valued at $878,000 after buying an additional 2,956 shares during the period. Institutional investors and hedge funds own 48.06% of the company’s stock.

Insider Transactions at Fulgent Genetics

In other Fulgent Genetics news, CEO Ming Hsieh sold 2,227 shares of the firm’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $18.26, for a total value of $40,665.02. Following the transaction, the chief executive officer now directly owns 703,711 shares of the company’s stock, valued at $12,849,762.86. This trade represents a 0.32 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold a total of 3,413 shares of company stock valued at $62,321 in the last ninety days. Corporate insiders own 31.76% of the company’s stock.

Fulgent Genetics Trading Down 4.5 %

Shares of FLGT opened at $17.13 on Wednesday. The firm has a market capitalization of $523.96 million, a PE ratio of -3.10 and a beta of 1.40. Fulgent Genetics, Inc. has a twelve month low of $16.56 and a twelve month high of $27.56. The stock’s 50 day moving average is $18.85 and its two-hundred day moving average is $20.73.

Wall Street Analysts Forecast Growth

FLGT has been the topic of several research reports. Piper Sandler decreased their target price on Fulgent Genetics from $26.00 to $22.00 and set a “neutral” rating on the stock in a research note on Monday, November 11th. StockNews.com downgraded shares of Fulgent Genetics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 27th.

View Our Latest Stock Report on Fulgent Genetics

Fulgent Genetics Profile

(Free Report)

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.

Recommended Stories

Institutional Ownership by Quarter for Fulgent Genetics (NASDAQ:FLGT)

Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.